📊 REGN Key Takeaways
Is Regeneron Pharmaceuticals, Inc.. (REGN) a Good Investment?
Regeneron demonstrates strong fundamental financial health with exceptional profitability (31.4% net margin), robust free cash flow generation ($4.1B annually), and fortress-like balance sheet with minimal leverage (0.06x debt/equity). However, modest revenue growth of only 1.0% YoY suggests mature market positioning and limited near-term expansion catalysts, warranting a BUY rather than STRONG_BUY rating.
Regeneron shows high-quality fundamentals: strong profitability, a 31.4% net margin, robust free cash flow generation, and an exceptionally strong balance sheet with low leverage and ample liquidity. The main limitation is modest recent revenue growth, but the company’s financial resilience and cash-producing capacity support a favorable fundamental outlook if it can sustain pipeline execution and margin discipline.
Why Buy Regeneron Pharmaceuticals, Inc.. Stock? REGN Key Strengths
- Exceptional net profit margin of 31.4% and operating margin of 24.9%, demonstrating pricing power and operational efficiency
- Outstanding liquidity with 4.13x current ratio and 222.2x interest coverage, providing financial flexibility
- Strong free cash flow conversion at 28.4% FCF margin with $4.1B generated annually despite capital intensity
- Fortress balance sheet with only 0.06x debt/equity ratio and $3.1B cash position, minimal financial risk
- Healthy return on equity (14.4%) and ROA (11.1%) showing efficient capital deployment
- High profitability with 24.9% operating margin and 31.4% net margin
- Excellent financial health, including 4.13x current ratio and just 0.06x debt-to-equity
- Strong cash generation with $4.08B in free cash flow and 28.4% FCF margin
REGN Stock Risks: Regeneron Pharmaceuticals, Inc.. Investment Risks
- Anemic revenue growth of only 1.0% YoY indicates market saturation, patent expiration risks, or competitive pressures
- Diluted EPS growth of 8.2% outpacing revenue growth suggests heavy reliance on share buybacks rather than organic growth
- Operating leverage fully captured with limited operating income growth relative to net income growth
- High insider activity (19 Form 4 filings in 90 days) warrants monitoring for potential concerns
- Revenue growth is currently modest at 1.0% YoY, which may limit operating leverage expansion
- Pharmaceutical earnings can be vulnerable to product concentration, patent cliffs, and pipeline execution risk
- Margins could face pressure from R&D intensity, competition, or reimbursement and regulatory changes
Key Metrics to Watch
- Revenue growth rate trending; need evidence of reversal from 1.0% YoY growth
- Product pipeline success and market adoption of new therapies to drive future organic growth
- Operating cash flow sustainability and capital allocation decisions (buybacks vs. R&D investment)
- Gross margin trends once disclosed, as margin compression could threaten profitability
- Debt levels and financial strategy, particularly use of balance sheet cash
- Revenue growth rate and product concentration trends
- Operating margin and free cash flow consistency
Regeneron Pharmaceuticals, Inc.. (REGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 28.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 4.13x current ratio provides a solid financial cushion.
REGN Profit Margin, ROE & Profitability Analysis
REGN vs Healthcare Sector: How Regeneron Pharmaceuticals, Inc.. Compares
How Regeneron Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Regeneron Pharmaceuticals, Inc.. Stock Overvalued? REGN Valuation Analysis 2026
Based on fundamental analysis, Regeneron Pharmaceuticals, Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Regeneron Pharmaceuticals, Inc.. Balance Sheet: REGN Debt, Cash & Liquidity
REGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Regeneron Pharmaceuticals, Inc..'s revenue has declined by 11% over the 5-year period, indicating business contraction. The most recent EPS of $34.77 reflects profitable operations.
REGN Revenue Growth, EPS Growth & YoY Performance
REGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.7B | $722.0M | $11.54 |
| Q2 2025 | $3.5B | $722.0M | $12.41 |
| Q1 2025 | $3.0B | $722.0M | $6.27 |
| Q3 2024 | $3.4B | $722.0M | $8.89 |
| Q2 2024 | $3.2B | $722.0M | $8.50 |
| Q1 2024 | $3.1B | $722.0M | $6.27 |
| Q3 2023 | $2.9B | $817.8M | $8.89 |
| Q2 2023 | $2.9B | $817.8M | $7.47 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Regeneron Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
REGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Regeneron Pharmaceuticals, Inc.. (CIK: 0000872589)
📋 Recent SEC Filings
❓ Frequently Asked Questions about REGN
What is the AI rating for REGN?
Regeneron Pharmaceuticals, Inc.. (REGN) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are REGN's key strengths?
Claude: Exceptional net profit margin of 31.4% and operating margin of 24.9%, demonstrating pricing power and operational efficiency. Outstanding liquidity with 4.13x current ratio and 222.2x interest coverage, providing financial flexibility. ChatGPT: High profitability with 24.9% operating margin and 31.4% net margin. Excellent financial health, including 4.13x current ratio and just 0.06x debt-to-equity.
What are the risks of investing in REGN?
Claude: Anemic revenue growth of only 1.0% YoY indicates market saturation, patent expiration risks, or competitive pressures. Diluted EPS growth of 8.2% outpacing revenue growth suggests heavy reliance on share buybacks rather than organic growth. ChatGPT: Revenue growth is currently modest at 1.0% YoY, which may limit operating leverage expansion. Pharmaceutical earnings can be vulnerable to product concentration, patent cliffs, and pipeline execution risk.
What is REGN's revenue and growth?
Regeneron Pharmaceuticals, Inc.. reported revenue of $14.3B.
Does REGN pay dividends?
Regeneron Pharmaceuticals, Inc.. pays dividends, with $370.3M distributed to shareholders in the trailing twelve months.
Where can I find REGN SEC filings?
Official SEC filings for Regeneron Pharmaceuticals, Inc.. (CIK: 0000872589) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is REGN's EPS?
Regeneron Pharmaceuticals, Inc.. has a diluted EPS of $41.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is REGN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Regeneron Pharmaceuticals, Inc.. has a BUY rating with 80% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is REGN stock overvalued or undervalued?
Valuation metrics for REGN: ROE of 14.4% (sector avg: 15%), net margin of 31.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy REGN stock in 2026?
Our dual AI analysis gives Regeneron Pharmaceuticals, Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is REGN's free cash flow?
Regeneron Pharmaceuticals, Inc..'s operating cash flow is $5.0B, with capital expenditures of $898.4M. FCF margin is 28.4%.
How does REGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 31.4% (avg: 12%), ROE 14.4% (avg: 15%), current ratio 4.13 (avg: 2).